Skip to content
DAEWOONG THERAPEUTICS

Pipeline

Proven in our own programs, and with global partners.

We prove our platforms on our own molecules and with partners. Two of our CLOPAM peptides already have Phase 1 INDs approved, three more programs head for IND in 2028, and global pharma companies are developing peptides, ADCs and antibodies on CLOPAM and Thermicra.

01 — In-house programs

Our own programs, on both platforms

We take our own molecules through the platforms to show what they do in the clinic.

CLOPAM 4 programs

Built on CLOPAM

  • DWRX 5001

    Endocrinology

    Peptide · microneedle patch

    Stage: Phase 1 IND approved

    Phase 1 IND approved

    1. DonePhase 1 IND approved · MFDSSep 2024

  • DWRX 5003

    Obesity

    Peptide · microneedle patch

    Stage: Phase 1 IND approved

    Phase 1 IND approved

    1. DonePhase 1 IND approved · MFDSSep 2025

  • DWRX 5028

    Rare skin disease

    Microneedle patch · weekly to monthly

    Stage: Preclinical

    Preclinical

    1. PlannedPhase 1 IND submission · FDA1Q 2028
    2. PartnerOpen to partnering Talk to our BD team

  • DWRX 5029

    Rare skin disease

    Microneedle patch · weekly

    Stage: Preclinical

    Preclinical

    1. PlannedPhase 1 IND submission · FDA2Q 2028
    2. PartnerOpen to partnering Talk to our BD team

Thermicra 2 programs

Built on Thermicra

  • DWRX 6001

    ADC · subcutaneous formulation

    Stage: Preclinical

    Preclinical

    1. PlannedGMP manufacturingQ4 2027 – Q1 2028
    2. PlannedIND filingQ2 – Q3 2028

  • DWRX 6102

    mAb · ultra-high concentration biobetter

    Stage: Preclinical

    Preclinical

    02 — Collaborations

    Global pharma is already developing on our platforms.

    Partners range from top-tier global pharma to R&D companies in Asia. Partner names stay confidential.

    • 6

      Collaborations

    • 2

      Platforms

    • 2025

      Active since

    CLOPAM 3 collaborations

    Explore CLOPAM

    • Collaboration

      In progress · since 2025

      Peptide · microneedle patch

      A top-tier global obesity & endocrinology company

    • Collaboration

      In progress · since 2025

      Peptide vaccine · microneedle patch

      An R&D company in Asia

    • Collaboration

      In progress · since 2026

      Two peptides · microneedle patch

      A top-tier global big pharma

    Thermicra 3 collaborations

    Explore Thermicra

    • Collaboration

      In progress · since 2025

      ADC · subcutaneous formulation

      A top-tier global ADC developer

    • Collaboration

      In progress · since 2026

      ADC · subcutaneous formulation

      An R&D stage ADC developer

    • Collaboration

      In progress · since 2026

      mAb · subcutaneous formulation

      A top-tier global immunology company

    03 — Platform development

    From lab to commercial scale

    Since 3Q 2026, CLOPAM patches have been made on fully automated, aseptic lines — to our knowledge, the world's first. Thermicra's aseptic GMP line follows in 2H 2027.

    CLOPAM

    GMP details
    1. Lab scale· Yongin
      Since 2024
    2. Pilot scale· HyangnamWorld first
      Since 3Q 2026
    3. Commercial scale· Osong
      2030

    Thermicra

    GMP details
    1. Preclinical & launch supply· Seongnam
      2H 2027
    2. Commercial supply· Osong
      Next · timing to come

    Bring your molecule to CLOPAM or Thermicra.

    Start where our partners did: a feasibility study on your own molecule.
    Discuss a program